Melperone, an atypical antipsychotic drug with clozapine-like effect on plasma prolactin: Contrast with typical neuroleptics

Human Psychopharmacology

Volumn 24, Issue 5, 2009, Pages 415-422

  Bobo, William V ^a,b   Jayathilake, Karuna ^a   Lee, Myung A ^a   Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

Clozapine; Hyperprolactinemia; Melperone; Neuroleptics; Prolactin; Typical antipsychotics

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MELPERONE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; PERPHENAZINE; PROLACTIN; THIORIDAZINE; TIOTIXENE; BUTYROPHENONE DERIVATIVE; METYLPERON;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG DOSE TITRATION; FEMALE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; BLOOD; MENTAL DISEASE; SEX DIFFERENCE;

ADULT; ANTIPSYCHOTIC AGENTS; BUTYROPHENONES; CLOZAPINE; FEMALE; HUMANS; MALE; MENTAL DISORDERS; PROLACTIN; SEX FACTORS;

EID: 70149115912     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1036     Document Type: Article

References (37)

1. Barbato L, Monge A, Stocchi F, Nordera G. 1996. Melperone in the treatment of iatrogenic psychosis in Parkinson's disease. Funct Neurol 11: 201-207.
2. Bjerkenstedt L. 1989. Melperone in the treatment of schizophrenia. Acta Psychiatrica Scand Suppl 352: 35-39.
3. Bjerkenstedt L, Gullberg B, Harnryd C, Sedvall G. 1977. Monoamine metabolite levels in cerebrospinal fluid of psychotic women treated with melperone or thiothixene. Arch Psychiatr Nervenkr 224: 107-118.
4. Bjerkenstedt L, Gullberg B, Harnryd C, Sedvall G. 1979. Relationships between clinical and biochemical effects of melperone and thiothixene in psychotic women. Archiv fur Psychiatrie und Nervekrankheiten 227: 181-192.
5. Bjerkenstedt L, Harnryd C, Grimm V, Gullberg B, Sedvall G. 1978. A double-blind comparison of melperone and thiothixene in psychotic women using a new rating scale, the CPRS. Archiv fur Psychiatrie und Nervekrankheiten 226: 156-162.
6. Byerly M, Suppes T, Tran QV, Baker RA. 2007. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 27(6): 639-661.
7. Christensen I, Geismar L, Kirkegaard A, Kirkegaard G. 1986. Additional studies on side effects of melperone in long-term therapy for 1-20 years in psychiatric patients. Arzneimittelforschung 36: 855-860.
8. Haddad PM, Wieck A. 2004. Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features and management. Drugs 64: 2291-2314.
9. Harnryd C, Bjerkenstedt L, Gullberg B. 1989. A clinical comparison of melperone and placebo in schizophrenic women on a milieu therapetuic ward. Acta Psychiatrica Scand Suppl 352: 40-47.
10. 1A receptor agonism. Brain Res 956: 349-357.
11. Kane J, Honigfeld G, Singer J, Meltzer H. 1988. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-796.
12. Kapur S, Remington G, Jones C, et al., 1996. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 153: 948-950.
13. Kapur S, Seeman P. 2001. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158: 360-369.
14. Kapur S, Zipursky R, Jones C, Remington G, Houle S. 2000. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157: 514-520.
15. Kirkegaard A, Kirkegaard G, Geismar L, Christensen I. 1981. Additional studies on adverse effects of melperone in long-term therapy for 1 to 15 years in psychiatric patients. Arzneimittelforschung 31: 737-740.
16. Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ. 2005. Predominant role of the 9-hydroxymetabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 162: 1010-1012.
17. Kuruvilla A, Peedicayil J, Srikrishna G, Kuruvilla K, Kanagasabapathy AS. 1992. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 19: 603-606.
18. Meltzer HY. 1985. Long-term effects of neuroleptic drugs on the neuroendocrine system. Adv Biochem Psychopharmacol 40: 59-68.
19. Meltzer HY, Busch DA, Fang VS. 1983. Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res 9: 271-283.
20. Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS. 1979. Effect of clozapine on human serum prolactin levels. Am J Psychiatry 136: 1550-1555.
21. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. 2003. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27: 1159-1172.
22. 2 pKi values. J Pharmacol Exp Ther 251: 238-246.
23. Meltzer HY, Sumiyoshi T, Jayathilake K. 2001. Melperone in the treatment of neuroleptic-resistant schizophrenia. Psychiatry Res 105: 201-209.
24. Molander L, Borgstrom L. 1983. Sedative effects and prolactin response to single oral dose of melperone. Psychopharmacology (Berl) 79: 142-147.
25. Molitch ME. 2005. Medication-induced hyperprolactinemia. Mayo Clin Proc 80: 1050-1057.
26. Motreja S, Subbakrishna DK, Subhash MN, Gangadhar BN, Janakiramaiah N, Parameshwara G. 1997. Gender but not stimulus parameters influence prolactin response to electroconvulsive therapy. Psychoneuroendocrinology 22: 337-348.
27. Naidoo U, Kinon BJ, Gilmore JA, Liu H, Halbrich UM. 2003. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 28(suppl 2): 69-82.
28. Nocjar C, Roth BL, Pehek EA. 2002. Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience 111: 163-176.
29. Nordstrom AL, Farde L, Wiesel FA, et al., 1993. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33: 227-235.
30. Prus AJ, Baker LE, Meltzer HY. 2004. Discriminative stimulus properties of 1.25 and 5.0 mg/kg doses of clozapine in rats: examination of the role of dopamine, serotonin, and muscarinic receptor mechanisms. Pharmacol Biochem Behav 77: 199-208.
31. Richelson E, Souder T. 2000. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci 68: 29-39.
32. Robertson GS, Matsumura H, Fibiger HC. 1994. Induction patterns of Foslike immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271: 1058-1066.
33. Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, Meltzer HY. 1993. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 266: 1374-1384.
34. Sumiyoshi T, Jayathilake K, Meltzer HY. 2003. A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia. Schizophr Res 62: 65-72.
35. Sumiyoshi T, Jayathilake K, Meltzer HY. 2002. The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia. Schizophr Res 59: 7-16.
36. Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS. 2001. 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, rennin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci 21: 3572-3579.
37. Wiesel FA, Farde L, Halldin C. 1989. Clinical melperone treatment blocks D2-dopamine receptors in the human brain as determined by PET. Acta Psychiatr Scand Suppl 352: 30-34.